Worst case: $50 mill upfront, but commitment to meet all the costs of the Phase 3. $250 m on FDA approval, 10% royalties
Best case: More upfront, additional commitments to fully fund manufacturing and toxicity etc and European and other non-US approval applications/negotiations – leaving Neuren free to spend any upfront, milestone and royalties on other indications etc
What will the deal be like? Head vs heart, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.46 |
Change
-0.500(2.39%) |
Mkt cap ! $2.650B | |||
| Open | High | Low | Value | Volume |
| $21.00 | $21.21 | $20.31 | $6.014M | 291.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 237 | $20.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.47 | 497 | 12 |
View Market Depth
| Last trade - 12.46pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.41 |
Change
-0.500 ( 3.09 %) |
||||
| Open | High | Low | Volume | ||
| $20.97 | $21.15 | $20.32 | 90086 | ||
| Last updated 13.03pm 30/05/2024 ? | |||||
| NEU (ASX) Chart |